High Court Won't Review Feraheme Investor Class Action
The U.S. Supreme Court on Monday refused to hear an appeal of the First Circuit's revival of a putative class action accusing AMAG Pharmaceuticals Inc. and its bank underwriters of misleading...To view the full article, register now.
Already a subscriber? Click here to view full article